BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 16, 2020
Management Tracks

Flagship picks Pfefer to lead Kintai, succeeding Tak

Flagship Pioneering has chosen former GSK vaccines executive Guillaume Pfefer to lead portfolio company Kintai, making him the firm’s second hire to take the title of CEO partner. Pfefer succeeds Paul-Peter Tak, who had led...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BioCentury | Jan 23, 2020
Preclinical News

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap into the microbiome’s links to human...
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

Amgen Inc. (NASDAQ:AMGN) said EVP and CFO David Meline will retire at year end. The pharma hired Peter Griffith as EVP, finance and said he will succeed Meline as CFO on Jan. 1. Griffith was...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level. With a platform that homes in on the structural elements...
BioCentury | Sep 12, 2019
Company News

Management tracks: Vifor, Kintai, Verge, Xellia, Syapse

Vifor Pharma Ltd. (SIX:VIFN) said Sanofi’s Klaus Henning Jensen will become CMO and a member of the executive committee, effective in January. A three-year veteran of the French pharma, Jensen has served as global therapeutic...
BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
Items per page:
1 - 10 of 13
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 16, 2020
Management Tracks

Flagship picks Pfefer to lead Kintai, succeeding Tak

Flagship Pioneering has chosen former GSK vaccines executive Guillaume Pfefer to lead portfolio company Kintai, making him the firm’s second hire to take the title of CEO partner. Pfefer succeeds Paul-Peter Tak, who had led...
BioCentury | Feb 29, 2020
Management Tracks

Brandicourt joins Alnylam's board: plus Bayer, Jazz, Halozyme, Arena, Aurinia, Adverum, Neoleukin, Centogene, Epirium, Insilico, Nouscom, Eloxx, Nordic, Summit,

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said Olivier Brandicourt will join its board. Brandicourt, who retired as CEO of Sanofi (Euronext:SAN; NASDAQ:SNY) last year, also plans to join Blackstone Group as a senior adviser....
BioCentury | Jan 23, 2020
Preclinical News

Kintai reveals preclinical validation for its microbiome-inspired small molecules, prioritizes obesity

The first set of preclinical data from Kintai’s microbiome-derived small molecule platform supports the idea that manipulating the enteric signaling network with small molecules is one way to tap into the microbiome’s links to human...
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

Amgen Inc. (NASDAQ:AMGN) said EVP and CFO David Meline will retire at year end. The pharma hired Peter Griffith as EVP, finance and said he will succeed Meline as CFO on Jan. 1. Griffith was...
BioCentury | Sep 26, 2019
Company News

Omega: Flagship’s latest venture into the chromatin white space

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level. With a platform that homes in on the structural elements...
BioCentury | Sep 12, 2019
Company News

Management tracks: Vifor, Kintai, Verge, Xellia, Syapse

Vifor Pharma Ltd. (SIX:VIFN) said Sanofi’s Klaus Henning Jensen will become CMO and a member of the executive committee, effective in January. A three-year veteran of the French pharma, Jensen has served as global therapeutic...
BioCentury | Aug 27, 2019
Company News

Aug. 27 Company Quick Takes: GSK licenses Ionis HBV program; plus Adaptimmune-Noile, Purdue, Presage-BMS, Kyowa, Alexion, Viela, Kintai, OncoNano

GSK opts into Ionis' HBV program Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....
Items per page:
1 - 10 of 13